Premium
Doxorubicin‐paclitaxel
Author(s) -
Biganzoli Laura,
Cufer Tanja,
Bruning Peter,
Coleman Robert E.,
Duchateau Luc,
Rapoport Bernardo,
Nooij Marianne,
Delhaye François,
Miles D.,
Sulkes Aaron,
Hamilton A.,
Piccart Martine
Publication year - 2002
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.10914
Subject(s) - medicine , doxorubicin , cardiotoxicity , anthracycline , regimen , ejection fraction , paclitaxel , heart failure , cyclophosphamide , chemotherapy , cardiology , breast cancer , cancer
Abstract BACKGROUND The potential cardiotoxicy of the doxorubicin‐paclitaxel regimen, when paclitaxel is given shortly after the end of the anthracycline infusion, is an issue of concern, as suggested by small single institution Phase II studies. METHODS In a large multicenter Phase III trial, 275 anthracycline naive metastatic breast carcinoma patients were randomized to receive either doxorubicin (60 mg/m 2 ) followed 30 minutes later by paclitaxel (175 mg/m 2 3‐hour infusion; AT) or a standard doxorubicin‐cyclophosphamide regimen (AC; 60/600 mg/m 2 ). Both treatments were given once every 3 weeks for a maximum of six cycles. Close cardiac monitoring was implemented in the study design. RESULTS Congestive heart failure (CHF) occurred in three patients in the AT arm and in one patient in the AC arm ( P = 0.62). Decreases in left ventricular ejection fraction to below the limit of normal were documented in 33% AT and 19% AC patients and were not predictive of CHF development. CONCLUSIONS AT is devoid of excessive cardiac risk among metastatic breast carcinoma patients, when the maximum planned cumulative dose of doxorubicin does not exceed 360 mg/m 2 . Cancer 2003;97:40–5. © 2003 American Cancer Society. DOI 10.1002/cncr.10914